Researchers are one step closer to developing eye drops to treat age-related macular degeneration

July 19, 2018, University of Birmingham
A gentleman with macular degeneration. Credit: University of Birmingham

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).

AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.

AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr. Felicity de Cogan, from the University of Birmingham's Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.

Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.

This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.

The technology behind the eye drops is a cell-penetrating peptide that can deliver the to the retina (the back of the eye). The scientists' pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.

The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.

Dr. de Cogan said: "For several years, our team has focused on the challenge of delivering drugs to the back of the eye.

"From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.

"Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases."

Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: "Cell-penetrating peptides will drive the next generation of treatment for people with AMD.

"They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment."

Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen said: "Macregen and the company's prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and .

"We will also pursue the necessary and required regulatory programmes to make these available to patients."

Explore further: Scientists develop revolutionary eye drops to treat age-related blindness

More information: De Cogan et al (2018). 'Topical Treatment for AMD: Non-Invasive Delivery and Efficacy of Ranibizumab and Bevacizumab in Rabbit and Porcine Eyes.' Investigative Ophthalmology & Visual Science.

The previous study, published in March 2017 was: De Cogan et al (2017). 'Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides.' Investigative Ophthalmology & Visual Science. DOI: 10.1167/iovs.16-20072

Related Stories

Scientists develop revolutionary eye drops to treat age-related blindness

May 15, 2017
Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.

A drug to treat retinal diseases with drops instead of injections

December 13, 2017
The Spanish firm Sylentis has developed a compound to treat diseases of the retina including age-related macular degeneration and diabetic retinopathy. The treatment is administered by ophthalmic drops instead of intraocular ...

New glaucoma treatment could ease symptoms while you sleep

April 11, 2018
Eye drops developed by UBC researchers could one day treat glaucoma while you sleep - helping to heal a condition that is one of the leading causes of blindness around the world.

Dispute on eye drop size fails to catch Supreme Court's eye

May 21, 2018
A dispute about the size of eye drops has failed to catch the eye of the Supreme Court.

Chemical engineer's contacts could help treat glaucoma

June 22, 2015
A McMaster PhD candidate has harnessed a component naturally found in tears to develop a contact lens-based drug delivery system for glaucoma patients.

Recommended for you

Sleep in your contacts, risk serious eye damage: CDC

August 16, 2018
(HealthDay)—A 59-year-old man was in the shower, wiping his eyes with a towel, when he heard a popping sound and felt pain shoot through his left eye.

Researchers reverse congenital blindness in mice

August 15, 2018
Researchers funded by the National Eye Institute (NEI) have reversed congenital blindness in mice by changing supportive cells in the retina called Müller glia into rod photoreceptors. The findings advance efforts toward ...

Autoimmune response drives vision loss in glaucoma

August 10, 2018
A research team from Massachusetts Eye and Ear and the Massachusetts Institute of Technology has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive ...

Is too much screen time harming children's vision?

August 6, 2018
As children spend more time tethered to screens, there is increasing concern about potential harm to their visual development. Ophthalmologists—physicians who specialize in medical and surgical eye care—are seeing a marked ...

Researchers chart a course for AI-aided diagnosis of degenerative eye conditions

August 1, 2018
A team of researchers from Johns Hopkins is leading the way in understanding how the advent of electronic medical records with large image databases and advances in artificial intelligence with deep learning can offer medical ...

Derivative of turmeric eye drops could treat glaucoma

July 24, 2018
A derivative of turmeric could be used in eye drops to treat the early stages of glaucoma, finds a new study led by UCL and Imperial College London researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.